Browse regulations

This regulation imposes a registration and licensing regime on persons engaged in brokering activities for defense articles and services. It requires annual registration with the Directorate of Defense Trade Controls, fees, and approval for various brokering actions including financing, arranging sales, or facilitating transfers. It applies to U.S. persons worldwide and foreign persons under U.S. ownership/control, with exemptions for certain activities like domestic sales, government employees, and purely administrative services.

This regulation creates a burdensome licensing regime over voluntary economic arrangements, imposing significant compliance costs and granting bureaucrats discretionary power over legitimate business activity. While stemming illicit arms proliferation is a legitimate goal, regulating brokers separately from the underlying transactions is overbroad and not narrowly tailored. The registration fees, approval requirements, and reporting burdens fall disproportionately on small businesses while doing little to enhance national security that could be achieved through targeted measures. It represents bureaucratic mission creep that restricts liberty and free enterprise without commensurate benefits.

Definitions section for DEA controlled substances regulations (21 CFR parts 1301-1308, 1309-1310, 1313). Defines key terms including anabolic steroid, basic class, dispenser, manufacturer, registrant, and numerous other terms related to controlled substances, listed chemicals, import/export, and regulatory processes.

Purely definitions; no independent compliance costs or operational burdens. Removes only interpretive guidance, causing legal uncertainty, arbitrary enforcement, and constitutional vagueness challenges. Essential for consistent application of the underlying Controlled Substances Act.

Implements the Mammography Quality Standards Act (MQSA) by establishing procedures for FDA-approved accreditation bodies to evaluate and accredit mammography facilities, setting national quality standards for mammography services, and ensuring consistent evaluation of facilities for compliance with safety and accuracy standards.

Creates a costly federal bureaucracy that duplicates state-level regulation, imposes compliance burdens on small facilities, and raises barriers to entry in healthcare. The $2+ trillion annual regulatory compliance costs demonstrate how such programs disproportionately harm consumers through higher prices and reduced access to services.

Regulation mandates that electrode lead wires and patient cables for medical devices comply with IEC 601-1 safety standard to prevent electrical hazards to patients, sets compliance dates, and provides an exemption process.

Deletion would risk patient electrocution during medical procedures. Market forces cannot ensure safety because patients cannot pre-assess risks, and irreversible harm occurs before liability deters. This regulation enforces a proven international standard; achieving equivalent protection without it would be administratively impossible and would expose countless patients to preventable lethal hazards.

FDA regulation requiring medical device manufacturers and importers to report within 10 days any correction or removal initiated to reduce health risks or remedy violations of the Food, Drug, and Cosmetic Act. Exempts routine servicing, market withdrawals for minor violations, stock recovery, and quality improvements that don't reduce risk. Requires detailed reporting including device identifiers, distribution lists, and event descriptions. Mandates 2-year record retention and permits FDA inspection and public disclosure with redactions for trade secrets and privacy.

Medical device failures pose catastrophic, non-obvious risks that market mechanisms alone cannot adequately detect or prevent. The asymmetric information between manufacturers and patients/doctors is extreme—defects often emerge only after widespread use. This regulation merely requires manufacturers to report actions they themselves deem necessary to address health risks, creating a centralized early-warning system that protects lives at relatively low compliance cost. Without it, dangerous devices would remain in circulation longer, harming patients and eroding trust in the medical system. The alternative—relying solely on tort litigation after injuries occur—is far costlier to society. The reporting burden is modest compared to the trillion-dollar health care system it oversees, and the transparency requirement aligns market incentives with safety without dictating how devices must be designed.

Requires manufacturers to notify the FDA 75 days before marketing a dietary supplement containing a new dietary ingredient, submitting safety evidence, ingredient details, and conditions of use. The FDA acknowledges receipt, imposes a 75-day waiting period before interstate commerce, and keeps notifications confidential for 90 days before public display (excluding trade secrets).

The premarket notification imposes substantial compliance costs and a 75-day delay that stifles innovation, disproportionately harm small businesses, and raise consumer prices. Safety is better determined through post-market surveillance, tort liability, and state regulation. The hidden tax of bureaucracy far exceeds any marginal safety benefit, while creating barriers to entry and distorting market competition.

FDA's NEPA implementation regulations require environmental assessments (EAs) for actions involving FDA-regulated products, with categorical exclusions for routine administrative activities and specific categories of drug, food, device, and tobacco product approvals that don't increase environmental exposure or affect endangered species.

These regulations create unnecessary bureaucratic delays for product approvals without meaningful environmental benefits, as FDA-regulated products rarely have significant environmental impacts. The paperwork burden diverts resources from actual safety reviews and creates barriers to market entry without improving public health outcomes.

FDA regulations establishing criteria for electronic records and electronic signatures to be considered trustworthy, reliable, and equivalent to paper records and handwritten signatures. Applies to electronic records created, modified, maintained, archived, retrieved, or transmitted under FDA requirements, including those under the Federal Food, Drug, and Cosmetic Act and Public Health Service Act. Sets forth validation, security, audit trail, and authentication requirements for both closed and open systems.

Electronic recordkeeping is essential for modern FDA operations. Without standardized criteria for electronic records and signatures, the agency cannot effectively regulate food, drugs, and medical devices in the digital age. This regulation enables efficient, secure record-keeping while maintaining integrity and accountability in a way that would be difficult to achieve through paper-based systems alone.

Establishes SSA policies for implementing the Privacy Act of 1974, governing disclosure of personal information, access to records, and correction procedures for Social Security Administration records.

Protects individuals' privacy rights and ensures proper handling of sensitive personal information by a federal agency that maintains extensive records on millions of Americans.

This Railroad Retirement Board regulation establishes procedures for reopening and revising final decisions on benefit claims. It sets time limits (12 months for any reason, 4 years with new evidence or error) and enumerates specific circumstances where decisions may be reopened at any time, including fraud, clerical errors, and certain statutory situations. It also includes exceptions for trivial errors and grants the Board discretion to waive restrictions.

Without this mechanism, the Board would lack any formal process to correct erroneous decisions, even when fraud is discovered or new evidence emerges. Beneficiaries erroneously denied benefits would have no recourse, and the agency couldn't rectify its own mistakes. The time limits and specific exceptions balance the need for finality with the imperative of justice, preventing both endless relitigation and the locking-in of demonstrably wrong decisions that cause real harm to retired railroad workers and their families.

Regulation outlines procedures for the Railroad Retirement Board to recover overpaid benefits, detailing recovery methods (direct repayment, setoff, actuarial adjustment), circumstances for waiver or administrative relief (without fault, financial hardship, equity), and standards for compromise, suspension, or termination of collection.

Deletion would either waste taxpayer funds by failing to recoup overpayments or enable arbitrary, harsh collections against retirees. The regulation balances fiscal responsibility with fairness through clear, standardized procedures that protect vulnerable beneficiaries while ensuring systematic recovery. Such a nuanced framework is essential for consistent, equitable administration that would be difficult to maintain without formal rules.

Federal regulations governing antidumping and countervailing duty proceedings, establishing procedures for trade remedy investigations and determinations under the Tariff Act of 1930 and related trade agreements.

These regulations create a complex administrative apparatus that distorts free trade, raises consumer prices, and protects domestic producers from competition through government intervention. The compliance costs and bureaucratic burden far exceed any purported benefits, while violating principles of free enterprise and limited government.

These regulations govern the issuance, transfer, and maintenance of Tennessee Valley Authority (TVA) Power Securities in book-entry form through the Federal Reserve Banks' Book-entry System. The rules establish how these securities are credited to accounts, transferred between participants, and how payments are made, with specific definitions for terms like Book-entry TVA Power Security, Participant, Security Entitlement, and Reserve Banks' roles as fiscal agent.

This regulation creates a specialized government securities system that adds unnecessary complexity to the financial markets. The book-entry system for TVA securities duplicates existing Treasury and Federal Reserve infrastructure, creating regulatory overhead without providing meaningful benefits to the public. It represents mission creep beyond TVA's core function of power generation and distribution, and the specialized rules create compliance costs for financial institutions that must navigate yet another regulatory regime.

Establishes comprehensive federal permitting process for LNG terminals and cross-border natural gas facilities under Natural Gas Act, requiring extensive applications (exhibits A-H), environmental reviews, pre-filing procedures, landowner notification, presidential permits, and annual capacity reporting to obtain Commission authorization.

Burdensome compliance costs deter new market entrants, protect incumbents, and delay energy infrastructure that would lower consumer prices. Federalizes state/local land use decisions in violation of Tenth Amendment. Vague 'public interest' standard enables arbitrary denial and regulatory capture. The unseen consequences include stifled innovation, reduced supply, and artificially higher energy costs that harm American households and small businesses.

Securities market regulation establishing rules for distribution participants, affiliated purchasers, passive market makers, and stabilizing activities to prevent market manipulation and maintain orderly markets during securities offerings.

This regulation creates a complex bureaucratic framework that distorts market signals and protects incumbent players through regulatory capture. The extensive definitions and exceptions benefit large institutions that can afford compliance while burdening smaller firms. The restrictions on trading during distributions artificially manipulate prices and prevent natural market discovery. Securities fraud laws already prohibit manipulation - this adds unnecessary regulatory overhead that increases costs for investors and reduces market efficiency.